Cytokinetics posts Q3 2026 results, plans nHCM filing for aficamten in Q4
The company reported $44.5 million in MYQORZO net product revenue and said it expects to submit a supplemental approval application for aficamten in non-obstructive HCM before year end.
SEC filing